Transcatheter Intervention for Coarctation of the Aorta: A Nordic Population-Based Registry With Long-Term Follow-Up.


Journal

JACC. Cardiovascular interventions
ISSN: 1876-7605
Titre abrégé: JACC Cardiovasc Interv
Pays: United States
ID NLM: 101467004

Informations de publication

Date de publication:
27 02 2023
Historique:
received: 21 04 2022
revised: 19 10 2022
accepted: 07 11 2022
entrez: 1 3 2023
pubmed: 2 3 2023
medline: 4 3 2023
Statut: ppublish

Résumé

Coarctation of the aorta (CoA), a congenital narrowing of the proximal descending thoracic aorta, is a relatively common form of congenital heart disease. Untreated significant CoA has a major impact on morbidity and mortality. In the past 3 decades, transcatheter intervention (TCI) for CoA has evolved as an alternative to surgery. The authors report on all TCIs for CoA performed from 2000 to 2016 in 4 countries covering 25 million inhabitants, with a mean follow-up duration of 6.9 years. During the study period, 683 interventions were performed on 542 patients. The procedural success rate was 88%, with 9% considered partly successful. Complications at the intervention site occurred in 3.5% of interventions and at the access site in 3.5%. There was no in-hospital mortality. During follow-up, TCI for CoA reduced the presence of hypertension significantly from 73% to 34%, but despite this, many patients remained hypertensive and in need of continuous antihypertensive treatment. Moreover, 8% to 9% of patients needed aortic and/or aortic valve surgery during follow-up. TCI for CoA can be performed with a low risk for complications. Lifetime follow-up after TCI for CoA seems warranted.

Sections du résumé

BACKGROUND
Coarctation of the aorta (CoA), a congenital narrowing of the proximal descending thoracic aorta, is a relatively common form of congenital heart disease. Untreated significant CoA has a major impact on morbidity and mortality. In the past 3 decades, transcatheter intervention (TCI) for CoA has evolved as an alternative to surgery.
OBJECTIVES
The authors report on all TCIs for CoA performed from 2000 to 2016 in 4 countries covering 25 million inhabitants, with a mean follow-up duration of 6.9 years.
METHODS
During the study period, 683 interventions were performed on 542 patients.
RESULTS
The procedural success rate was 88%, with 9% considered partly successful. Complications at the intervention site occurred in 3.5% of interventions and at the access site in 3.5%. There was no in-hospital mortality. During follow-up, TCI for CoA reduced the presence of hypertension significantly from 73% to 34%, but despite this, many patients remained hypertensive and in need of continuous antihypertensive treatment. Moreover, 8% to 9% of patients needed aortic and/or aortic valve surgery during follow-up.
CONCLUSIONS
TCI for CoA can be performed with a low risk for complications. Lifetime follow-up after TCI for CoA seems warranted.

Identifiants

pubmed: 36858664
pii: S1936-8798(22)02098-2
doi: 10.1016/j.jcin.2022.11.007
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

444-453

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures This work was funded by the Swedish state under the ALF agreement (grant 236611) and the Swedish Heart-Lung Foundation (grant 20180644) and Forskningsstiftelsen vid kardiologiska sektionen SU/Ostra Hospital. This study received no financial or other industry support. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Peter Eriksson (P)

University of Gothenburg, Institute of Medicine, Sahlgrenska Academy, Gothenburg, Sweden. Electronic address: peter.eriksson@vgregion.se.

Jaana Pihkala (J)

Helsinki University Hospital, University of Helsinki, Helsinki, Finland; European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart (http://guardheart.ern-net.eu).

Annette S Jensen (AS)

European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart (http://guardheart.ern-net.eu); Rigshospitalet-Copenhagen University Hospital, Copenhagen, Denmark.

Gaute Dohlen (G)

Oslo University Hospital Rikshospitalet, Oslo, Norway.

Petru Liuba (P)

Skane University Hospital, Lund, Sweden.

Hakan Wahlander (H)

University of Gothenburg, Institute of Clinical Science, Sahlgrenska Academy, Gothenburg, Sweden.

Gunnar Sjoberg (G)

Astrid Lindgren Children's Hospital and Department of Children's and Women's Health, Karolinska Institutet, Stockholm, Sweden.

Joanna Hlebowicz (J)

Skane University Hospital, Lund, Sweden.

Eva Furenas (E)

University of Gothenburg, Institute of Medicine, Sahlgrenska Academy, Gothenburg, Sweden.

Elisabeth Leirgul (E)

Haukeland University Hospital, Bergen, Norway.

Magnus Settergren (M)

Department of Cardiology, Karolinska University Hospital and Division of Cardiology, Department of Medicine, Karolinska Institute, Stockholm, Sweden.

Kanyalak Vithessonthi (K)

Oslo University Hospital Rikshospitalet, Oslo, Norway.

Niels-Erik Nielsen (NE)

Linköping University Hospital, Linköping, Sweden.

Christina Christersson (C)

Department of Medical Sciences, Uppsala University, Sweden.

Lars Sondergaard (L)

European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart (http://guardheart.ern-net.eu); Rigshospitalet-Copenhagen University Hospital, Copenhagen, Denmark.

Juha Sinisalo (J)

Helsinki University Hospital, University of Helsinki, Helsinki, Finland; European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart (http://guardheart.ern-net.eu).

Jens Erik Nielsen-Kudsk (JE)

Aarhus University Hospital, Aarhus, Denmark.

Mikael Dellborg (M)

University of Gothenburg, Institute of Medicine, Sahlgrenska Academy, Gothenburg, Sweden.

Signe H Larsen (SH)

European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart: ERN GUARD-Heart (http://guardheart.ern-net.eu); Rigshospitalet-Copenhagen University Hospital, Copenhagen, Denmark; Aarhus University Hospital, Aarhus, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH